Roche, Boehringer Drugs Wins Approval for Lung Disease
This article is for subscribers only.
Roche Holding AG and Boehringer Ingelheim GmbH won approval for the first therapies in the U.S. to treat the deadly lung disease idiopathic pulmonary fibrosis.
The Food and Drug Administration said it cleared Roche’s Esbriet, known chemically as pirfenidone, and Boehringer’s Ofev, known as nintedanib, for use in the lung-scarring disease that kills 60 percent to 80 percent of patients within five years and, until now, had no approved drugs in the U.S. Roche acquired Esbriet from InterMune Inc. in a deal that closed last month.